Forward Pharma A/S
FWPAY
Other OTC300.00
USD
-100.50
- -
Forward Pharma A/S
FWPAY
(Other OTC)
Recent
price
300.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Forward Pharma A/S (FWPAY), a Denmark-based biopharmaceutical company founded in 2005 and headquartered in Copenhagen, focuses on the development of proprietary formulations of dimethyl fumarate (DMF), including FP187, as an immunomodulatory compound for treating inflammatory diseases such as psoriasis and neurological conditions like multiple sclerosis; the company previously operated subsidiaries in Leipzig, Germany, and the United States. From 2005 to 2017, it advanced clinical programs for these indications before granting Biogen an irrevocable license to its entire intellectual property portfolio through a settlement and license agreement effective February 2017, receiving a non-refundable cash payment of $1.25 billion and returning EUR 917.7 million to shareholders via capital reduction in September 2017. In recent developments, Forward Pharma initiated a solvent liquidation process in 2025 following the substantial completion of its corporate restructuring plan, while facing a tender offer from Mason Capital Management LLC launched in May 2024 at DKK 74.8 million ($437.00 per ADS or 0.76 DKK per ordinary share), which was extended multiple times through mid-2024 and resulted in limited tenders before Nasdaq delisting proceedings; the company currently maintains no significant ongoing operations.
BlackRock (BLK) Stock Sinks As Market Gains: Here's Why
Uranium Energy (UEC) Exceeds Market Returns: Some Facts to Consider
Forward Pharma A/S Announces Termination of its American Depositary Receipts (“ADR”) Facility